Appetite and body composition
Does Ipamorelin cause weight gain?
The mouse study challenges a simple fat-loss claim. The ferret study was trying to preserve weight during illness.
Weight and fat in GH-deficient mice
Lall and colleagues studied mice with deficient and intact growth-hormone systems. Both groups gained weight during Ipamorelin treatment; fat-pad weights and leptin increased too. Leptin is a hormone produced by fat tissue.
The result that troubles the easy slimming story is the response in GH-deficient mice. Some of the adiposity effect persisted with little growth hormone available. For me, that finding seriously weakens the claim that releasing GH necessarily produces fat loss. A human body-composition trial would have to do the deciding.
Less weight loss in cisplatin-treated ferrets
The 2024 ferret experiment concerned weight loss induced by cisplatin. Ipamorelin inhibited that loss by approximately 24% in the delayed phase, during 48–72 h, while providing no anti-emetic effect.
Preserving weight during that illness model was a desirable research outcome. A healthy person's wish to lose fat asks the opposite question. This is why the direction of a weight change matters as much as its existence.
Human weight changes remain unmeasured
The published human benefit trial studied eating after bowel surgery. It supplies no controlled answer about fat loss, muscle gain or ordinary weight gain from prolonged Ipamorelin use.
Community descriptions of a leaner appearance can coincide with changes in diet, training, water retention and other substances. The evidence that would persuade me is measured human fat and lean mass, alongside safety outcomes. The benefits page follows the other claims often attached to the same hormone mechanism.